Počet záznamů: 1
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system
- 1.0013815 2026 RIV GB eng J
Šmilauerová, Kristýna - Štach, Martin - Mucha, Martin - Vaníková, Šárka - Rychlá, Jana - Otáhal, PavelG
Targeting of acute myeloid leukemia by five-gene engineered T cells expressing transgenic T-cell receptor specific to WT1, chimeric antigenic receptor specific to GM-CSF receptor, bispecific T-cell engager specific to CD33, and tEGFR suicide gene system.
Immunotherapy advances. Vol. 5, no. 1 (2025), art. no. ltaf022. ISSN 2732-4303
Grant: Ministerstvo zdravotnictví NU22-05-00374
Institucionální podpora: RVO:00023736
Klíčová slova: WT-1 * AML * piggyBac transposon
Cite Score: 8.300, rok: 2024; SJR: 1.565, rok: 2024; IF: 4.9, rok: 2024
DOI: 10.1093/immadv/ltaf022
Anotace: Cancer immunotherapy with transgenic T-cell receptor-engineered T cells (TCR-T) enables the targeting of intracellular tumor-specific antigens; in contrast, chimeric antigen receptor-modified T cells (CAR-T) mediate tumor cell killing via the recognition of surface antigens. In the case of acute myeloid leukemia, the lack of leukemia-specific surface antigens limits the efficacy of CAR-T cells; therefore, TCR-T cells may represent a more targeted immunotherapy approach. However, the tumor immunosuppressive environment eliminates the best-functioning, high-avidity TCR-T cells, thus creating a need for novel, enhanced TCR-T cells. The presented strategy, utilizing a single piggyBac transposon vector, enables the complex redirection of T-cell specificity against acute myeloid leukemia by inserting TCR, CAR, BiTE constructs, along with a tEGFR gene suicide system.
Počet záznamů: 1